Contacts

Tremendous success for MedinCell’s €30 million capital increase for qualified investors

February 11, 2021

Offer widely oversubscribed: 2.5 times the total amount of the capital increase
Strong support from French and international leading shareholders and investors


MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the “Company”), is today announcing the successful completion of its €29.8 million capital increase via a placement with French and international qualified investors through an accelerated bookbuilding process (the “Offering”).

Bryan, Garnier & Co. Limited1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.